"ClinPhone, which develops technology for clinical trials, rose 11.2p, or 13.3%, to 97.5p after it rejected a takeover approach by Parexel, a similar US firm. The group said the offer "materially" undervalued the company and its prospects."
http://www.guardian.co.uk/business/2008/feb/19/northernrock.banking5
Tuesday, February 19, 2008
CNP
